$FBLG SEC Filings

Filed On	Filing
19 Oct 2026	EFFECT
19 Oct 2026	EFFECT
13 Oct 2026	POS AM
13 Oct 2026	POS AM
13 Oct 2026	D
08 Oct 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant +1 more THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of October 7, 2026, is entered into by and between FIBROBIOLOGICS, INC., a Delaware corporation, (the “Company”) and Peak One Opportunity Fund, L.P., a Delaware limited partn...
18 Sep 2026	8-K: Submission of Matters to a Vote of Security Holders; Regulation FD Disclosure HOUSTON, September 17, 2026 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics" or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeut...
17 Sep 2026	SCHEDULE 13D
16 Sep 2026	D
15 Sep 2026	Form 4: Khoja Hamid, Chief Scientific Officer Received 298,508 shares as a grant or award ($500K) · Granted 298,508 Warrant (Right to Buy)
15 Sep 2026	8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between FibroBiologics, Inc., a Delaware corporation (the “Company”), and Hamid Khoja, an individual (the “Purchaser”).
09 Sep 2026	DEFA14A
01 Sep 2026	Form 3: Steinberg Leigh, Director No securities owned
24 Aug 2026	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
14 Aug 2026	SCHEDULE 13G
31 Jul 2026	10-Q
31 Jul 2026	Proxy statement: special meeting on September 17, 2026
24 Jul 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
17 Jul 2026	PRE 14A
16 Jul 2026	EFFECT

Comments